Australian FY22 earnings preview - CSL
CSL Limited (CSL) is Australia's largest drugmaker, one of the world's largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines.
Share this:
CSL Limited (CSL) is Australia's largest drugmaker, one of the world's largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines.
CSL is the third largest company in the ASX200 with an index weighting of ~6.9% and reports its Full Year numbers this Wednesday the 17th of August.
COVID-19 provided a headwind for CSL's supply chains and the collection of plasma, an essential raw material used to produce many of CSL's therapies, which account for almost half of CSL's sales. In the first 1H 2022, CSL reported a 5% fall in Net Profit After Tax (NPAT) to $1.76bn.
In December 2021, CSL announced it would acquire 100% of Vifor Pharma Ltd, a global speciality pharmaceutical company with leadership in renal disease and iron deficiency. After a delay to do with antitrust issues, the US$11.7bn deal received regulatory clearance and was recently completed.
While the deal will have no bearing on the company’s earnings for 2022 it will provide the company with a bigger footprint within the industry, a more diversified earnings stream and boost CSL’s earnings in 2023.
Along with strong demand for plasma products and a drop in the fees paid to plasma donors (boosted payment incentives no longer needed to attract donors as they were during COVID-19), the company ends this financial year in a strong position.
CSL’s earnings are heavily screwed to the first half of the year. Full Year NPAT is expected to be in the range of $2.15bn-$2.25bn.
CSL Daily Chart
The decline from the $342.75 high of February 2020 to the $240.10 low in February 2022 completed a correction and the CSL share price is eyeing trend channel resistance near $310/12 where profit taking/selling is likely to emerge.
Should the CSL share price break above the resistance at $310/12 and then above resistance at $320/21 it would likely open up a retest and break of the $342.75 high.
Source Tradingview. The figures stated are as of August 15, 2022. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation
How to trade with City Index
You can trade with City Index by following these four easy steps:
- Open an account, or log in if you’re already a customer
• Open an account in the UK
• Open an account in Australia
• Open an account in Singapore
- Search for the company you want to trade in our award-winning platform
- Choose your position and size, and your stop and limit levels
- Place the trade
CSL Limited (CSL) is Australia's largest drugmaker, one of the world's largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines.
CSL is the third largest company in the ASX200 with an index weighting of ~6.9% and reports its Full Year numbers this Wednesday the 17th of August.
COVID-19 provided a headwind for CSL's supply chains and the collection of plasma, an essential raw material used to produce many of CSL's therapies, which account for almost half of CSL's sales. In the first 1H 2022, CSL reported a 5% fall in Net Profit After Tax (NPAT) to $1.76bn.
In December 2021, CSL announced it would acquire 100% of Vifor Pharma Ltd, a global speciality pharmaceutical company with leadership in renal disease and iron deficiency. After a delay to do with antitrust issues, the US$11.7bn deal received regulatory clearance and was recently completed.
While the deal will have no bearing on the company’s earnings for 2022 it will provide the company with a bigger footprint within the industry, a more diversified earnings stream and boost CSL’s earnings in 2023.
Along with strong demand for plasma products and a drop in the fees paid to plasma donors (boosted payment incentives no longer needed to attract donors as they were during COVID-19), the company ends this financial year in a strong position.
CSL’s earnings are heavily screwed to the first half of the year. Full Year NPAT is expected to be in the range of $2.15bn-$2.25bn.
CSL Daily Chart
The decline from the $342.75 high of February 2020 to the $240.10 low in February 2022 completed a correction and the CSL share price is eyeing trend channel resistance near $310/12 where profit taking/selling is likely to emerge.
Should the CSL share price break above the resistance at $310/12 and then above resistance at $320/21 it would likely open up a retest and break of the $342.75 high.
Source Tradingview. The figures stated are as of August 15, 2022. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as containing any financial product advice or financial product recommendation
- Open a Forex.com account, or log in if you’re already a customer.
- Search for the pair you want to trade in our award-winning platform.
- Choose your position and size, and your stop and limit levels.
- Place the trade.
Related tags:
Latest market news
Open an account in minutes
Experience award-winning platforms with fast and secure execution, and enjoy tight spreads from 0.5 pts on FX and 0.3 pts on indices.
Economic calendar
Web Trader platform
Our sophisticated web-based platform is packed with features.
Related articles
ASX 200 Slides as Oil, Yields and Rate Risks Hit Sentiment
The ASX 200 suffered its worst week in six months as surging oil, higher bond yields and renewed rate-hike bets drove a broad risk-off move.
Cyclical stocks sniff out better times ahead
Different economies, different drivers, similar price action. The German DAX, ASX 200 and Russell 2000 are all hinting at a more optimistic view on the global economy.
SK Hynix IPO: Everything You Need to Know About SK Hynix
Learn everything you need to know about the SK Hynix IPO, including its Nasdaq listing, valuation, financials, ownership, competitors and investment risks.
This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.
StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.
In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.
StoneX Financial Pte. Ltd. is not under any obligation to update this report.
Trading CFDs carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit www.forex.com/en-sg/terms-and-policies for the complete Risk Disclosure Statement.